New therapies against HCV: Expected risks and challenges associated with their use in the liver transplant setting

Journal of Hepatology

Volumn 57, Issue 6, 2012, Pages 1361-1367

  Mccaughan, Geoffrey W ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; BOCEPREVIR; CYCLOSPORIN; EVEROLIMUS; LAMIVUDINE; MONOCLONAL ANTIBODY; PEGINTERFERON; PROTEIN TYROSINE KINASE; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; TELAPREVIR;

ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CROSS RESISTANCE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; GENOTYPE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PORTAL HYPERTENSION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

EID: 84869226272     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.07.035     Document Type: Note

References (65)

1. G.T. Everson, J. Trotter, L. Forman, M. Kugelmas, A. Halprin, and B. Fey Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy Hepatology 42 2005 255 262
2. X. Forns, M. Garcia-Retortillo, T. Serrano, A. Feliu, F. Suarez, and M. de la Mata Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation J Hepatol 39 2003 389 396
3. J.A. Carrion, E. Martinez-Bauer, G. Creso, S. Ramirez, S. Perez-del Pulgar, and J.C. Garcia-Valdecasis Antiviral therapy increases the risk of bacterial infections in HCV infected cirrhotic patients awaiting liver transplantation: a retrospective study J Hepatol 50 2009 719 728
4. N. Chalasani, C. Manzarbeitia, P. Ferenci, W. Vogel, R.J. Fontana, and M. Voigt Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials Hepatology 41 2005 289 298
5. N. Bzowej, D.R. Nelson, N.A. Terrault, G.T. Everson, L.L. Teng, and A. Prabhakar PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus Liver Transpl 17 2010 528 538
6. M. Berenguer Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin J Hepatol 49 2008 274 287
7. N.A. Terrault, and C. Hepatitis Therapy before and after liver transplantation Liver Transpl 14 2008 S58 S66
8. T. Bizollon, P. Pradat, J.Y. Mabrut, M. Chevallier, M. Adham, and S. Radenne Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C Am J Transplant 5 2005 1909 1913
9. T. Fukuhara, A. Taketomi, T. Motomura, S. Okano, A. Ninomiya, and T. Abe Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C Gastroenterology 139 2010 1577 1585
10. C.M. Lange, D. Moradpour, A. Doehring, H.A. Lehr, B. Mullhaupt, and S. Bibert Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection J Hepatol 55 2010 322 327
11. G.W. McCaughan, N.A. Shackel, and D.G. Bowen Liver transplantation and hepatitis C: will understanding the interleukin-28B polymorphisms improve outcomes? Liver Transpl 17 2011 219 221
12. K.E. Sherman, S.L. Flamm, N.H. Afdhal, D.R. Nelson, M.S. Sulkowski, and G.T. Everson Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
13. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
14. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
15. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
16. J.M. Pawlotsky New antiviral agents for hepatitis C F1000 Biol Rep 4 2012 5
17. M.W. Fried, M. Buti, G.J. Dore, R. Flisiak, P. Ferenci, and I.M. Jacobson TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the PILLAR Phase IIb study Hepatology 54 2011 1429A
18. D. Dieterich, T. Asselah, D. Guyader, T. Berg, E. Ceausu, and L. Preotescu SILEN-C3: treatment for 12 or 24 weeks with BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-naive patients with chronic genotype 1 HCV infection Hepatology 54 2011 378A
19. C. Hezode, G.M. Hirschfield, W. Ghesquiere, W. Sievert, M. Rodriguez-Torres, and S.D. Shafran BMS-790052, a NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV genotype 1 or 4 patients: phase 2b AI444010 study interim week 12 results Hepatology 54 2011 474A
20. S. Zeuzem, P. Buggisch, K. Agarwal, M.P. Manns, P. Marcellin, and G.R. Foster Dual, triple and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) and PegIFN/RBV for up to 28 days in treatment-naive genotype 1 HCV subjects Hepatology 52 2010 400A
21. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, and R. Ghalib Combination therapy with BMS-650032 alone or with PegIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype Hepatology 52 2010 877A
22. N.A. Terrault, C. Cooper, L.A. Balart, D. Larrey, T.D. Box, and E. Yoshida High sutstained virologic response (SVR24) rates with response-guided danoprevir (DNV; RG7227) plus PegIFN alfa-2a (40 KD) and ribavirin (P/R) in treatment-naive HCV Genotype 1 (G1) patients: Results from the Atlas Study Hepatology 54 2011 398A
23. E. Lawitz, J.P. Lalezari, T. Hassanein, K.V. Kowdley, F. Poordad, and A.M. Sheikh Once-daily PSI-7977 plus Peg/RBV in treatment-naive patients with HCV GT1: robust end of treatment response rates are sustained post treatment Hepatology 54 2011 472A
24. M.S. Sulkowski, T. Asselah, P. Ferenci, J.O. Stern, G. Kukolj, and W.O. Boecher Treatment with the second generation HCV protease inhibitor BI201335 results in high and consistent SVR rates - results from SILEN-C1 in treatment-naive patients across different baseline factors Hepatology 54 2011 473A
25. S. Zeuzem, T. Asselah, P. Angus, J.P. Zarski, D. Larrey, and B. Mullhaupt Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection Gastroenterology 141 2011 2047 2055
26. D. Larrey, C. Carenco, D. Guyader, N. Boyer, Y. Benhamou, and G.-P. Pageaux High sustained virological response (SVR) rate with danoprevir for only 14 days associated with pre-interferon-alfa-2a and ribavirin in treatment chronic HCV genotype 1 patients Hepatology 54 2011 793A
27. D.R. Nelson, E. Gane, I.M. Jacobson, A.M. Di Bisceglie, K. Alves, and M.J. Koziel VX-222/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype 1 HCV patients treated for 12 weeks: Zenith study, SVR12 interim analysis Hepatology 54 2011 1435A
28. S. Zeuzem, P. Buggisch, K. Agarwal, P. Marcellin, D. Sereni, and H. Klinker The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C Hepatology 55 2012 749 758
29. J.M. Vierling, F. Poordad, E. Lawitz, R. Ghalib, W.M. Lee, and N. Ravendhran Once daily Narlaprevir (NVR; SCH 900518) and Ritonavir (RTV) in combination with peginterferon alfa-2b/ribavirin (PR) for 12 weeks plus 12 weeks PR in treatment-naive patients with HCV genotype 1 (G1): SVR results from next-1, a phase 2 study Hepatology 54 2011 1439A
30. N. Izumi, Y. Asahina, O. Yokosuka, F. Imazeki, N. Kawada, and A. Tamori Combination therapy of treatment-naive and nonresponder patients with HCV genotype 1 infection with BMS-790052, An NS5A replication complex inhibitor, in combination with peginterferon alfa-2a and ribavirin Hepatology 54 2011 1439A
31. F. Suzuki, K. Chayama, Y. Kawakami, J. Toyota, Y. Karino, and S. Mochida BMS-790052, An NS5A replication complex inhibitor, in combination with peginterferon alpha-2B and ribavirin in Japanese treatment-naive and nonresponder patients with chronic HCV genotype 1 infection Hepatology 54 2011 1441A
32. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, and R. Ghalib Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
33. E. Gane, C.A. Stedman, R.H. Hyland, R.D. Sorensen, W.T. Symonds, and R. Hindes Once daily PSI-7977 plus RBV: pegylated interferon alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3 Hepatology 54 2011 377A
34. I. Gilead Sciences Gilead announces data for genotype 1 null responder hepatitis C patients enrolled in ELECTRON study 2012 Gilead Sciences, Inc Foster City, California
35. K. Chayama, S. Takahashi, J. Toyota, Y. Karino, K. Ikeda, and H. Ishikawa Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders Hepatology 55 2012 728 742
36. S. Zeuzem, V. Soriano, T. Asselah, J.P. Bronowicki, E. Ceausu, and A. Lohse Virologic response to an interferon-free regimen of BI201335 and BI207127, with and without Ribavirin, in treatment-naive patients with chronic Hepatology 54 2011 1436A
37. E.J. Gane, S.K. Roberts, C.A. Stedman, P.W. Angus, B. Ritchie, and R. Elston Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
38. A.J. Thompson, and J.G. McHutchinson Will IL28B polymorphisms remain relevant in the era of direct acting antiviral agents? Hepatology 56 2012 373 381
39. C. Hezode, C. Dorival, F. Zoulim, T. Poynard, P. Mathurin, and S. Pol Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non-responders. First results of the French early access programme (ANRS CO20-CUPIC) J Hepatol 56 2012 S1 S20
40. G. Tritto, Z. Bechlis, V. Stadlbauer, N. Davies, R. Frances, and N. Shah Evidence of neutrophil functional defect despite inflammation in stable cirrhosis J Hepatol 55 2011 574 581
41. J.M. Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 2011 1742 1751
42. F. Zoulim, S. Radenne, and C. Ducerf Management of patients with decompensated hepatitis B virus associated cirrhosis Liver Transpl 14 2008 S1 7
43. R.J. Fontana, H.W. Hann, R.P. Perrillo, J.M. Vierling, T. Wright, and J. Rakela Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy Gastroenterology 123 2002 719 927
44. H. Innes, S. Hutchinson, S.H. Allen, D.N. Bhatacharyya, P. Bramley, and T.E. Delahooke Excess live-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care Hepatology 54 2011 1547 1558
45. F.D. Gordon, R.T. Chung, M.P. Curry, T.D. Schiano, S. Emre, and G.J. Babcock Monoclonal antibody MBL-HCV1 suppresses return of HCV following liver transplantation Hepatology 54 2011 1434A
46. I. Fofana, F. Xiao, C. Thumann, J. Lupberger, P. Leyssen, and J.H. Neyts Synergy of entry inhibitors and direct acting antivirals or interferon-alfa identifies novel antiviral combination for hepatitis C virus infection Hepatology 54 2011 401A
47. I. Fofana, S.E. Krieger, F. Grunert, S. Glauben, F. Xiao, and S. Fafi-Kremer Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes Gastroenterology 139 2010 953 964
48. K. Lacek, K. Vercauteren, K. Grzyb, M. Naddeo, L. Verhoye, and M.P. Slowokowski Novel human SR-B1 antibodies prevent infection and dissemination of HCV in vitro and in humanised mice J Hepatol 57 2012 17 23
49. J. Lupberger, M.B. Zeisel, F. Xiao, C. Thumann, I. Fofana, and L. Zona EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy Nat Med 17 2011 589 595
50. J.J. Kiser, J.R. Burton, P.L. Anderson, and G.T. Everson Review and management of drug interactions with boceprevir and telaprevir Hepatology 55 2012 1620 1628
51. E. Hulskotte, S. Gupta, F. Xuan, M. van Zutven, E. O'Mara, and H.P. Feng Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers Hepatology 2012 in press (on line)
52. V. Garg, R. van Heeswijk, J.E. Lee, K. Alva, P. Nadkarnrni, and X. Luo Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus Hepatology 54 2011 20 27
53. T.M. McCashland, A. Marco, M.A. Olivera-Martinez, M. Mauricio Garcia-Saenz de Sicilia, S. Sandeep Mukherjee, and A. Fedja Early experience with triple drug therapy (telaprevir, pegylated interferon α 2A and ribavirin) in patients on cyclosporine A for hepatitis C recurrence after liver transplantation Liver Transpl 18 2012 S99
54. A. Coilly, B. Roche, D. Botta-Fridlund, V. Leroy, P.G. Pageaux, and S.N. Si-Ahmed A first multicentric experience of protease inhibitors for severe hepatitis C recurrence after liver transplantation Liver Transpl 18 2012 S84
55. M. Schilsky, T. Sam, E. Tichy, C. Caldwell, S. Jakab, and S. Emre Boceprevir, peginterferon and ribavirin (PEGIFN/RIB) as triple antiviral therapy for severe recurrent hepatitis C post liver transplant: an early single center experience Am J Transplant 12 2012 433
56. S. Pungpapong, J. Murphy, T. Henry, R. Satyanarayana, B. Rosser, and M. Yataco P: P234-III initial experience utilizing telaprevir with peginterferon and ribavirin for treatment of hepatitis C genotype 1 after liver transplantation Am J Transplant 12 2012 430
57. A.P. de Oliveira Pereira, H.J. Shin, A. Safdar, H. Tobias, B. Gelb, and G. Morgan Post liver transplant therapy with telaprevir for recurrent hepatitis C Am J Transplant 12 2012 430
58. T. Sam, E. Tichy, S. Emre, and M. Schilsky P237-III pharmacokinetic effects of boceprevir co-administration on cyclosporine exposure in liver transplant recipients Am J Transplant 12 2012 430
59. J.R. Burton, and G.T. Everson Initial experience with telaprevir for treating hepatitis C virus in liver recipients: virologic response, safety, and tolerability Am J Transplant 12 2012 188
60. C.C. Rogers, D.R. Stevens, M. Kim, T. Ghaziani, R. Malik, and M.P. Curry P239-III telaprevir can be used safely with concomitant tacrolimus in the post-transplant setting Am J Transplant 12 2012 431
61. A. Coilly, B. Roche, D. Botta-Fridlund, V. Leroy, P.G. Pageaux, and S.N. Si-Ahmed Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience J Hepatol 56 2012 S21 S44
62. R.J. Fontana, E.A. Hughes, H. Appelman, R. Hindes, D. Dessislava, and M. Bifano A case report of successful interferon, ribavirin and daclastavir therapy for recurrent cholestatic hepatitis following liver transplantation Liver transpl 18 2012 1053 1059
63. Achillion Achillion reports clinical data on portfolio of protease inhibitors 2012 Achillion New Haven, Connecticut
64. M. Garcia-Retortillo, X. Forns, A. Feliu, E. Moitinho, J. Costa, and M. Navasa Hepatitis C virus kinetics during and immediately after liver transplantation Hepatology 35 2002 680 687
65. R.B. Guerrero, K.P. Batts, L.J. Burgart, S.L. Barrett, J.J. Germer, and J.J. Poterucha Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study Mod Pathol 13 2000 229 237